公开(公告)号：US20150307522A1

公开(公告)日：2015-10-29

申请号：US14694039

申请日：2015-04-23

Applicant: PFIZER INC.

Inventor： DAVID LAWRENCE FIRMAN GRAY ,  LEI ZHANG ,  JENNIFER ELIZABETH DAVOREN ,  AMY BETH DOUNAY ,  IVAN VIKTOROVICH EFREMOV ,  SCOT RICHARD MENTE ,  CHAKRAPANI SUBRAMANYAM

IPC: C07D519/00 ,  C07D471/04 ,  C07D491/147 ,  C07D495/14 ,  C07D513/04

CPC classification number: C07D519/00 ,  A61K31/4355 ,  A61K31/4365 ,  A61K31/437 ,  A61K31/497 ,  A61K31/4985 ,  A61K31/506 ,  A61K31/513 ,  A61K31/519 ,  C07D471/04 ,  C07D491/048 ,  C07D491/147 ,  C07D495/04 ,  C07D495/14 ,  C07D513/04

Abstract: The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), schizotypal personality disorder, cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), ADHD, Parkinson's disease, anxiety, and depression.